2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis
Copyright © 2023 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved..
Septic bursitis (SB) is a common condition accounting for one third of all cases of inflammatory bursitis. It is often related to professional activities. Management is heterogeneous and either ambulatory or hospital-based, with no recommendations available. This article presents recommendations for managing patients with septic bursitis gathered by 18 rheumatologists from the French Society for Rheumatology work group on bone and joint infections, 1 infectious diseases specialist, 2 orthopedic surgeons, 1 general practitioner and 1 emergency physician. This group used a literature review and expert opinions to establish 3 general principles and 11 recommendations for managing olecranon and prepatellar SB. The French Health authority (Haute Autorité de santé [HAS]) methodology was used for these recommendations. Designed for rheumatologists, general practitioners, emergency physicians and orthopedic surgeons, they focus on the use of biological tests and imaging in both outpatient and inpatient management. Antibiotic treatment options (drugs and duration) are proposed for both treatment modalities. Finally, surgical indications, non-drug treatments and prevention are covered by specific recommendations.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
---|---|
Enthalten in: |
Joint bone spine - 91(2024), 2 vom: 23. März, Seite 105664 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Darrieutort-Laffite, Christelle [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-Bacterial Agents |
---|
Anmerkungen: |
Date Completed 01.03.2024 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jbspin.2023.105664 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364871202 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364871202 | ||
003 | DE-627 | ||
005 | 20240301232141.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jbspin.2023.105664 |2 doi | |
028 | 5 | 2 | |a pubmed24n1313.xml |
035 | |a (DE-627)NLM364871202 | ||
035 | |a (NLM)37995861 | ||
035 | |a (PII)S1297-319X(23)00143-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Darrieutort-Laffite, Christelle |e verfasserin |4 aut | |
245 | 1 | 0 | |a 2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.03.2024 | ||
500 | |a Date Revised 01.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved. | ||
520 | |a Septic bursitis (SB) is a common condition accounting for one third of all cases of inflammatory bursitis. It is often related to professional activities. Management is heterogeneous and either ambulatory or hospital-based, with no recommendations available. This article presents recommendations for managing patients with septic bursitis gathered by 18 rheumatologists from the French Society for Rheumatology work group on bone and joint infections, 1 infectious diseases specialist, 2 orthopedic surgeons, 1 general practitioner and 1 emergency physician. This group used a literature review and expert opinions to establish 3 general principles and 11 recommendations for managing olecranon and prepatellar SB. The French Health authority (Haute Autorité de santé [HAS]) methodology was used for these recommendations. Designed for rheumatologists, general practitioners, emergency physicians and orthopedic surgeons, they focus on the use of biological tests and imaging in both outpatient and inpatient management. Antibiotic treatment options (drugs and duration) are proposed for both treatment modalities. Finally, surgical indications, non-drug treatments and prevention are covered by specific recommendations | ||
650 | 4 | |a Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Recommendations | |
650 | 4 | |a Septic bursitis | |
650 | 4 | |a Soft tissue infection | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
700 | 1 | |a Coiffier, Guillaume |e verfasserin |4 aut | |
700 | 1 | |a Aïm, Florence |e verfasserin |4 aut | |
700 | 1 | |a Banal, Fréderic |e verfasserin |4 aut | |
700 | 1 | |a Bart, Géraldine |e verfasserin |4 aut | |
700 | 1 | |a Chazerain, Pascal |e verfasserin |4 aut | |
700 | 1 | |a Couderc, Marion |e verfasserin |4 aut | |
700 | 1 | |a Coquerelle, Pascal |e verfasserin |4 aut | |
700 | 1 | |a Ducourau Barbary, Emilie |e verfasserin |4 aut | |
700 | 1 | |a Flipo, René-Marc |e verfasserin |4 aut | |
700 | 1 | |a Faudemer, Maël |e verfasserin |4 aut | |
700 | 1 | |a Godot, Sophie |e verfasserin |4 aut | |
700 | 1 | |a Hoffmann, Céline |e verfasserin |4 aut | |
700 | 1 | |a Lecointe, Thibaut |e verfasserin |4 aut | |
700 | 1 | |a Lormeau, Christian |e verfasserin |4 aut | |
700 | 1 | |a Mulleman, Denis |e verfasserin |4 aut | |
700 | 1 | |a Piot, Jean-Maxime |e verfasserin |4 aut | |
700 | 1 | |a Senneville, Eric |e verfasserin |4 aut | |
700 | 1 | |a Seror, Raphaèle |e verfasserin |4 aut | |
700 | 1 | |a Voquer, Christine |e verfasserin |4 aut | |
700 | 1 | |a Vrignaud, Arthur |e verfasserin |4 aut | |
700 | 1 | |a Guggenbuhl, Pascal |e verfasserin |4 aut | |
700 | 1 | |a Salliot, Carine |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Joint bone spine |d 2000 |g 91(2024), 2 vom: 23. März, Seite 105664 |w (DE-627)NLM106960067 |x 1778-7254 |7 nnns |
773 | 1 | 8 | |g volume:91 |g year:2024 |g number:2 |g day:23 |g month:03 |g pages:105664 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jbspin.2023.105664 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 91 |j 2024 |e 2 |b 23 |c 03 |h 105664 |